![]() |
|
|
Vol. 283, Issue 2, 833-842, 1997
-Acetylmethadol,
l-
-Acetyl-N-normethadol and
l-
-Acetyl-N,N-dinormethadol: Comparisons with
Morphine and Methadone in Suppression of the Opioid Withdrawal Syndrome
in the Dog
Brain Imaging Section, Intramural Research Program, National
Institute on Drug Abuse, Baltimore, Maryland (D.B.V.), and
Center
for Chemical Dependence, Johns Hopkins Bayview Medical Center,
Baltimore, Maryland (D.R.J.)
l-
-Acetyl-N-normethadol (nor-LAAM) and
l-
-acetyl-N,N-dinormethadol (dinor-LAAM) are active
metabolites of the opiate l-
-acetylmethadol (LAAM),
and they contribute to the prolonged actions of the parent compound.
Single doses of nor-LAAM, dinor-LAAM, LAAM, methadone and morphine were
given intravenously to the chronic spinal dog to determine acute,
single-dose effects and their ability to suppress withdrawal in
morphine-dependent dogs. These opioids produced dose-dependent
antinociception, decreases in body temperature and pupillary
constriction. For these measures, dinor-LAAM was 1.5 to 3 times and
nor-LAAM 6 to 12 times as potent as LAAM. Five hours after the acute
administration of LAAM or either of the metabolites, a 1-mg/kg dose of
naltrexone given intravenously produced withdrawal, indicating the
presence of acute physical dependence. In dogs physically dependent on
a daily dose of 125 mg of morphine, nor-LAAM was 9 times as potent as
either LAAM or dinor-LAAM in suppressing spontaneous withdrawal 40 hr
after the last dose of morphine. The efficacies of LAAM and its
demethylated metabolites in the dog for producing acute opiate effects
were comparable with those of morphine and methadone. There was a
trend, however, for LAAM to suppress the expression of abstinence more fully than either metabolite. The usefulness of LAAM as a treatment for
opiate addiction is likely due in part to the equivalent efficacies and
higher potencies of its nor and dinor metabolites.
This article has been cited by other articles:
![]() |
T. N. Nanovskaya, S. V. Deshmukh, R. Miles, S. Burmaster, and M. S. Ahmed Transfer of L-{alpha}-Acetylmethadol (LAAM) and L-{alpha}-Acetyl-N-normethadol (norLAAM) by the Perfused Human Placental Lobule J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 205 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Oda and E. D. Kharasch Metabolism of Methadone and levo-alpha -Acetylmethadol (LAAM) by Human Intestinal Cytochrome P450 3A4 (CYP3A4): Potential Contribution of Intestinal Metabolism to Presystemic Clearance and Bioactivation J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1021 - 1032. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Oda and E. D. Kharasch Metabolism of levo-{alpha}-Acetylmethadol (LAAM) by Human Liver Cytochrome P450: Involvement of CYP3A4 Characterized by Atypical Kinetics with Two Binding Sites J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 410 - 422. [Abstract] [Full Text] |
||||
![]() |
T. Eissenberg, M. L. Stitzer, G. E. Bigelow, A. R. Buchhalter, and S. L. Walsh Relative Potency of levo-alpha -Acetylmethadol and Methadone in Humans under Acute Dosing Conditions J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 936 - 945. [Abstract] [Full Text] |
||||